Elzonris

tagraxofusp

Table of contents

Opinion

The European Medicines Agency has recommended the refusal of the marketing authorisation for Elzonris, a medicine intended for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN).

The Agency issued its opinion on 23 July 2020. The company that applied for authorisation, Stemline Therapeutics B.V, may ask for re-examination of the opinion within 15 days of receiving the opinion.

Key facts

Name
Elzonris
Agency product number
EMEA/H/C/005031
International non-proprietary name (INN) or common name
  • tagraxofusp
Active substance
  • tagraxofusp
Date opinion adopted
23/07/2020
Company name
Stemline Therapeutics B.V.
Status
Negative
Application type
Initial authorisation

How useful was this page?

Add your rating